Hubbry Logo
Catharanthus roseusCatharanthus roseusMain
Open search
Catharanthus roseus
Community hub
Catharanthus roseus
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Catharanthus roseus
Catharanthus roseus
Catharanthus roseus
View on Wikipedia
from Wikipedia

Catharanthus roseus
Close-up of pink Catharanthus roseus flower with five petals and darker central eye
Close-up of a pink Catharanthus roseus flower
Scientific classification Edit this classification
Kingdom: Plantae
Clade: Tracheophytes
Clade: Angiosperms
Clade: Eudicots
Clade: Asterids
Order: Gentianales
Family: Apocynaceae
Genus: Catharanthus
Species:
C. roseus
Binomial name
Catharanthus roseus
Synonyms
  • Vinca rosea L.
  • Pervinca rosea (L.) Gaterau
  • Lochnera rosea (L.) Rchb. ex Spach
  • Ammocallis rosea (L.) Small

(See also Synonyms section)

White flower with yellow center

Catharanthus roseus, commonly known as bright eyes, Cape periwinkle, graveyard plant, Madagascar periwinkle, old maid, pink periwinkle, rose periwinkle,[2] is a perennial species of flowering plant in the family Apocynaceae. It is native and endemic to Madagascar, but is grown elsewhere as an ornamental and medicinal plant, and now has a pantropical distribution. It is a source of the drugs vincristine and vinblastine, used to treat cancer.[3] It was formerly included in the genus Vinca as Vinca rosea.

It has many vernacular names among which are arivotaombelona or rivotambelona, tonga, tongatse or trongatse, tsimatiririnina, and vonenina.[4]

Taxonomy

[edit]

Two varieties are recognized

  • Catharanthus roseus var. roseus
Synonymy for this variety
Catharanthus roseus var. angustus Steenis ex Bakhuizen f.[5]
Catharanthus roseus var. albus G.Don[6]
Catharanthus roseus var. occellatus G.Don[6]
Catharanthus roseus var. nanus Markgr.[7]
Lochnera rosea f. alba (G.Don) Woodson[8]
Lochnera rosea var. ocellata (G.Don) Woodson
  • Catharanthus roseus var. angustus (Steenis) Bakh. f.[9]
Synonymy for this variety
Catharanthus roseus var. nanus Markgr.[10]
Lochnera rosea var. angusta Steenis[11]

Evolution

[edit]

Following the Jurassic period approximately 185 million years ago, the supercontinent Gondwana separated into two distinct geographic areas: east Gondwana (Madagascar, Antarctica, Australia and the Indian subcontinent) and west Gondwana (Africa, South America), leading to the geographic location of the island of Madagascar. It is now known as one of the fourth largest islands in the world, developing its own extraordinary biodiversity in isolation. This has led to unique species and a diverse array of approximately 15000 plants and over 10000 angiosperm species, 84% being endemic to Madagascar. It was within this ecosystem that the periwinkle came to existence.

The presence of over 200 alkaloids within the plant, including vinblastine and vincristine and their use in cancer drugs, are a result of the plant's response to environmental threats and pressures. Studies have shown that compounds isolated from C. roseus are examples of secondary metabolites, which have contributed to the plant's ability to defend itself against herbivores and other pathogens, allowing it an advantage from predators or other pathogens within their immediate environment. These secondary metabolites would contrast from primary metabolites used for growth and development. Studies have shown that biosynthetic pathways, such as catharanthine and vindoline, accumulate separately in the plant, allowing for it to evade common pests such as Egyptian Cotton leafworm, Spodoptera littoralis.

Within single cell genome analysis, gene clusters within C. roseus have been identified through MIA biosynthesis, including the Vinca alkaloids. Within plants, the genome evolved through different forms of gene duplication, which involved either whole chromosomes, segmental duplications, tandem or dispersed duplications. Millions of years of evolution led to the encoding of the enzymes for the complex biosynthetic pathways we see in C. roseus, which further accounts for the many compounds synthesized, as well as recent studies highlighting the role of random spontaneous mutations further influencing a plant's genetic information.

Description

[edit]
Close-up view of flower in morning
In morning

Catharanthus roseus is an evergreen subshrub or herbaceous plant growing 1 m (39 in) tall. The leaves are oval to oblong, 2.5–9 cm (1.0–3.5 in) long and 1–3.5 cm (0.4–1.4 in) wide, glossy green, hairless, with a pale midrib and a short petiole 1–1.8 cm (0.4–0.7 in) long; they are arranged in opposite pairs. The flowers range from white with a yellow or red center to dark pink with a darker red center, with a basal tube 2.5–3 cm (1.0–1.2 in) long and a corolla 2–5 cm (0.8–2.0 in) diameter with five petal-like lobes. The fruit is a pair of follicles 2–4 cm (0.8–1.6 in) long and 3 mm (0.1 in) wide.[12][13][14][15]

Ecology

[edit]

In its natural range along the dry coasts of southern Madagascar, Catharanthus roseus is considered weedy and invasive, often self-seeding prolifically in disturbed areas along roadsides and in fallow fields.[16][17] It is also widely cultivated and is naturalized in subtropical and tropical areas of the world such as Australia, Bangladesh, India, Malaysia, Pakistan, and the United States.[12] It is so well adapted to growth in Australia that it is listed as a noxious weed in Western Australia and the Australian Capital Territory,[18] and also in parts of eastern Queensland.[19]

Pale Pink with Red Centre Cultivar

Cultivation

[edit]

As an ornamental plant, it is appreciated for its hardiness in dry and nutritionally deficient conditions, popular in subtropical gardens where temperatures never fall below 5–7 °C (41–45 °F), and as a warm-season bedding plant in temperate gardens. It is noted for its long flowering period, throughout the year in tropical conditions, and from spring to late autumn, in warm temperate climates. Full sun and well-drained soil are preferred. Numerous cultivars have been selected, for variation in flower colour (white, mauve, peach, scarlet, and reddish-orange), and also for tolerance of cooler growing conditions in temperate regions.

Notable cultivars include 'Albus' (white flowers), 'Grape Cooler' (rose-pink; cool-tolerant), the Ocellatus Group (various colours), and 'Peppermint Cooler' (white with a red centre; cool-tolerant).[12]

In the U.S. it often remains identified as "Vinca" although botanists have shifted its identification and it often can be seen growing along roadsides in the south.

In the United Kingdom it has gained the Royal Horticultural Society's Award of Garden Merit[20] (confirmed 2017).[21]

Uses

[edit]

Traditional

[edit]

In Ayurveda (Indian traditional medicine) the extracts of its roots and shoots, although poisonous, are used against several diseases. In traditional Chinese medicine, extracts from it have been used against numerous diseases, including diabetes, malaria, and Hodgkin's lymphoma.[22][13] In the 1950s, vinca alkaloids, including vinblastine and vincristine, were isolated from Catharanthus roseus while screening for anti-diabetic drugs.[23] This chance discovery led to increased research into the chemotherapeutic effects of vinblastine and vincristine. Conflict between historical indigenous use, and a patent from 2001 on C. roseus-derived drugs by western pharmaceutical companies, without compensation, has led to accusations of biopiracy.[24]

Medicinal

[edit]

Vinblastine and vincristine, chemotherapy medications used to treat several types of cancers, are found in the plant[25][26][27][28] and are biosynthesised from the coupling of the alkaloids catharanthine and vindoline.[29] The newer semi-synthetic chemotherapeutic agent vinorelbine, used in the treatment of non-small-cell lung cancer,[27][30] can be prepared either from vindoline and catharanthine[27][31] or from the vinca alkaloid leurosine,[32] in both cases via anhydrovinblastine.[31] The insulin-stimulating vincoline has been isolated from the plant.[33][34]

A periwinkle shrub
Dark pink colour

Research

[edit]

Despite the medical importance and wide use, the desired alkaloids (vinblastine and vincristine) are naturally produced at very low yields. Additionally, it is complex and costly to synthesize the desired products in a lab, resulting in difficulty satisfying the demand and a need for overproduction.[35] Treatment of the plant with phytohormones, such as salicylic acid[36] and methyl jasmonate,[37][38] have been shown to trigger defense mechanisms and overproduce downstream alkaloids. Studies using this technique vary in growth conditions, choice of phytohormone, and location of treatment. Concurrently, there are various efforts to map the biosynthetic pathway producing the alkaloids to find a direct path to overproduction via genetic engineering.[39][40]

C. roseus is used in plant pathology as an experimental host for phytoplasmas.[41] This is because it is easy to infect with a large majority of phytoplasmas, and also often has very distinctive symptoms such as phyllody and significantly reduced leaf size.[42]

In 1995 and 2006 Malagasy agronomists and American political ecologists studied the production of Catharanthus roseus around Fort Dauphin and Ambovombe and its export as a natural source of the alkaloids used to make vincristine, vinblastine and other vinca alkaloid cancer drugs. Their research focused on the wild collection of periwinkle roots and leaves from roadsides and fields and its industrial cultivation on large farms.[43][44][45]

Biology

[edit]

Rosinidin is the pink anthocyanidin pigment found in the flowers of C. roseus.[46] Lochnericine is a major alkaloid in roots.[47]

Toxicity

[edit]

C. roseus can be extremely toxic if consumed orally by humans, and is cited (under its synonym Vinca rosea) in the Louisiana State Act 159. All parts of the plant are poisonous. On consumption, symptoms consist of mild stomach cramps, cardiac complications, hypotension, systematic paralysis eventually leading to death.[48]

According to French botanist Pierre Boiteau, its poisonous properties are made known along generations of Malagasy people as a poison consumed in ordeal trials, even before the tangena fruit was used. This lent the flower one of its names vonenina, from Malagasy: vony enina meaning "flower of remorse".[49]

[edit]
  • Deep-red Catharanthus roseus
    Deep-red Catharanthus roseus
  • This one was grown in Bangladesh as an ornamental plant in a flower tub in the balcony of a house
    This one was grown in Bangladesh as an ornamental plant in a flower tub in the balcony of a house
  • Off-white Catharanthus roseus
    Off-white Catharanthus roseus
  • White with red-centered Catharanthus roseus
    White with red-centered Catharanthus roseus
  • Red Catharanthus roseus
    Red Catharanthus roseus
  • White periwinkle with thin petals
    White periwinkle with thin petals
  • Catharanthus roseus in Kerala
    Catharanthus roseus in Kerala
  • Purple Catharanthus roseus
    Purple Catharanthus roseus
  • Periwinkle From a garden at Cox's Bazar, Bangladesh
    Periwinkle From a garden at Cox's Bazar, Bangladesh
  • Catharanthus roseus in Ishwardi, Bangladesh
    Catharanthus roseus in Ishwardi, Bangladesh
  • Flower bud in West Bengal, India
    Flower bud in West Bengal, India
  • Periwinkle Plant in India
    Periwinkle Plant in India
  • Common periwinkle plant in India
    Common periwinkle plant in India
  • Catharanthus roseus in Pakistan
    Catharanthus roseus in Pakistan
  • Grown in Malaysia
    Grown in Malaysia
  • Flower plant raised in India temples
    Flower plant raised in India temples
  • Seed pod and seeds
    Seed pod and seeds
  • Matured fruits of Madagascar Periwinkle
    Matured fruits of Madagascar Periwinkle
  • Immature fruits of Madagascar periwinkle
    Immature fruits of Madagascar periwinkle
  • Pacifica Burgundy Halo – Madagascar Periwinkle
    Pacifica Burgundy Halo – Madagascar Periwinkle
  • Red cultivar of Madagascar Periwinkle
    Red cultivar of Madagascar Periwinkle
  • Potted Plant in New Delhi
    Potted Plant in New Delhi
  • Seeds
    Seeds
  • A fully bloomed white plant
    A fully bloomed white plant
  • A rare mutation of Periwinkle flower which causes an additional petal(6), found in Chandannagar
    A rare mutation of Periwinkle flower which causes an additional petal(6), found in Chandannagar

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Catharanthus roseus

View on Grokipedia
from Grokipedia

Catharanthus roseus (L.) G. Don., commonly known as Madagascar periwinkle, is a herbaceous or in the family, native and endemic to . It grows 30–100 cm tall with glossy, opposite leaves and produces salverform flowers featuring five petals in shades of pink, white, or purple with a darker eye, blooming continuously in suitable climates. Widely cultivated as an ornamental for its attractive foliage and long-lasting blooms, the plant has naturalized pantropically and exhibits invasive tendencies in some disturbed habitats. Its defining characteristic lies in the production of potent alkaloids, notably and , which inhibit formation and are clinically employed in regimens for treating hematologic malignancies such as and Hodgkin's lymphoma. These compounds, isolated through extensive research, underscore the plant's transition from traditional folk remedies to a cornerstone of modern .

Taxonomy and Nomenclature

Classification and Synonyms

Catharanthus roseus (L.) G. Don belongs to the kingdom Plantae, phylum Tracheophyta, class Magnoliopsida, order Gentianales, family Apocynaceae, genus Catharanthus, and species C. roseus. The binomial name derives from the basionym Vinca rosea L., published in 1753, with the current combination established by George Don in 1837–1838. The species has several accepted synonyms, reflecting historical taxonomic placements within genera such as Vinca and Lochnera, prior to its segregation into Catharanthus based on morphological distinctions like corolla tube length and fruit structure. Key synonyms include Vinca rosea L., Hottonia littoralis Lour., Lachnea rosea (L.) Rchb., and Lochnera rosea (L.) Rchb. These reflect nomenclatural revisions, with Vinca rosea persisting in older botanical and horticultural literature due to superficial similarities with true Vinca species in the Apocynaceae. No subspecies are currently recognized, though varietal forms like C. roseus var. roseus have been noted in some floras.

Etymology and Common Names

The genus name Catharanthus derives from the Greek words katharos, meaning "pure," and anthos, meaning "flower," referring to the plant's immaculate white-flowered varieties. The specific epithet roseus is Latin for "rosy" or "rose-colored," alluding to the typical pinkish hues of its flowers. Originally classified as Vinca rosea by in 1759 within the periwinkle genus, it was transferred to by George Don in the early 19th century to reflect its distinct phylogenetic position in the family. Common names for Catharanthus roseus vary regionally and often reflect its ornamental appeal or native origin, including (emphasizing its Madagascar provenance), rosy periwinkle, , and annual . In tropical regions, it is also known as old maid, pink periwinkle, or running myrtle, though the latter can cause confusion with true species due to superficial floral similarities.

Evolutionary and Genetic Origins

Phylogenetic History

Catharanthus roseus occupies a basal position within the family, specifically in the paraphyletic subfamily Rauvolfioideae and tribe Vinceae, as determined by phylogenomic analyses incorporating over 1,000 species and extensive and nuclear data. This placement reflects the family's early diversification, with Rauvolfioideae characterized by traits such as sinistrorsely contorted corolla lobes, non-lignified anthers, colporate , and non-comate seeds, diverging from more derived subfamilies around 70 million years ago during the to transition. Molecular phylogenetic studies using complete plastid genomes have reinforced this positioning, identifying C. roseus as divergent relative to advanced genera like and within , with shared ancestral features in gene content and structure but variations in pseudogene presence and repeat regions. The genus is monotypic, comprising only C. roseus, which suggests limited speciation events in its lineage, potentially linked to its adaptation to island environments in . Divergence time estimates from genome-scale indicate that C. roseus separated from the closest relatives in the – clade approximately 36 to 65 million years ago, aligning with the Eocene radiation of order, where belongs. These estimates derive from calibrated molecular clocks incorporating fossil constraints and multi-gene alignments, highlighting the role of vicariance and climatic shifts in shaping asterid diversification. markers, such as simple sequence repeats unique to C. roseus, further aid in resolving intra-family relationships and tracking evolutionary markers for breeding and conservation.

Genome Characteristics

The genome of Catharanthus roseus is diploid with a chromosome number of 2n=16, consisting of eight pairs that include two metacentric, four subtelocentric, and two telocentric s. Early estimates placed the nuclear at approximately 738 Mb, though recent high-quality assemblies have reported assembled sizes ranging from 561.7 Mb to 572.1 Mb, with over 97% of the sequence anchored to the eight pseudochromosomes. Multiple assemblies have been produced, with chromosome-scale versions achieved using long-read sequencing technologies like PacBio and scaffolding. A 2023 assembly scaffolded 561.7 Mb into eight pseudochromosomes, achieving a scaffold N50 of 71.2 Mb and covering 99.3% of expected genes based on BUSCO analysis, highlighting low fragmentation and high completeness. Another contemporaneous effort yielded a 572.1 Mb assembly with 556.4 Mb anchored, enabling detailed of metabolic pathways. These assemblies have facilitated identification of approximately 27,000 protein-coding genes, with notable expansions in families such as AP2/ERF, which regulate terpenoid () biosynthesis. Genomic features include gene clusters associated with specialized metabolism, particularly TIAs like vinblastine precursors. The ORCA gene cluster, comprising AP2/ERF transcription factors ORCA3, ORCA4, and ORCA5, spans a single scaffold and coordinately activates downstream TIA pathway genes such as strictosidine synthase and . These clusters exhibit physical proximity, potentially aiding co-regulation, though the genome shows no extensive whole-genome duplication events beyond those shared with related species. The plastid genome, separately sequenced, measures 154,950 with a typical quadripartite structure, including a large single-copy region of 85,765 .

Botanical Description

Morphology and Anatomy

Catharanthus roseus is an evergreen herbaceous perennial or subshrub in the family, typically reaching heights of 30 to 100 cm with an erect to spreading, bushy growth habit and semi-woody stems at the base. The stems are branched, slender, and produce a white milky characteristic of the family, which is present throughout the plant. Leaves are simple, , ovate to oblong in shape, measuring 2.5 to 9 cm in length and 1 to 3.5 cm in width, with entire margins, a prominent midvein, and glossy dark green surfaces that are glabrous or sparsely pubescent. Flowers arise axillary, solitary or in pairs on short peduncles, featuring a funnel-shaped corolla with five overlapping petals, a long narrow tube, and colors ranging from white to pink or purple; the corolla diameter is approximately 2.5 to 3.5 cm. The fruit comprises two slender, divergent follicles, each 2 to 4 cm long, that dehisce longitudinally to release numerous black, grooved, cylindrical seeds. Anatomically, the leaves are dorsiventral, possessing a single layer of epidermal cells covered by a thin and fewer trichomes compared to related species, with anomocytic stomata primarily on the abaxial surface. Stem cross-sections reveal a central surrounded by vascular bundles in a ring, with laticifers distributed throughout the tissues. systems are typically fibrous and shallow, supporting the plant's adaptation to various soils, though detailed histological features such as and pericycle are consistent with norms.

Reproductive Biology

Catharanthus roseus exhibits a mixed mating system characterized by self-compatibility, with intra-flower self-pollination frequently occurring as the stigma contacts pollen from the same flower's dehisced anthers. Autonomous self-pollination results in seed set in more than 30% of flowers, though pollinator visits substantially enhance fruit set and the number of seeds per fruit. Cross-pollination, mediated primarily by nectar-seeking insects such as bees, predominates and contributes to the high genetic diversity observed in natural populations, indicating allogamy as the primary reproductive mode despite autogamous capability. Flowers are zygomorphic, salverform structures with a five-lobed corolla, typically or with a colored eye, arranged in axillary cymes; occurs sequentially, with flowering initiating around 10 weeks post-germination when plants reach 10-15 cm in height and persisting indefinitely in suitable conditions. The breeding system lacks , enabling both self and without barriers like spatial separation of reproductive organs in most strains, though rare variants exist. Cleistogamous flowers, which ensure without anther-stigma exposure, have been induced experimentally but do not occur naturally. Post-pollination, the superior develops into paired, slender follicles that dehisce longitudinally upon maturity, each containing 20-50 small, cylindrical with a dark brown testa. is primarily anemochorous and hydrochorous, aided by wind and water, with secondary via elaiosomes attracting in some contexts. The plant's habit and continuous flowering support prolific production, facilitating its invasive spread in tropical regions.

Habitat and Ecology

Native Distribution

Catharanthus roseus is endemic to , with its native range restricted to the eastern and southern regions of the island. The thrives in the seasonally dry tropical , commonly occurring in coastal sandy locations, dunes, river banks, savannah vegetation, and forest edges. It prefers well-drained soils such as and , and is adapted to habitats including scrublands, grasslands, , and disturbed areas. In these environments, it functions as a or herbaceous , often self-seeding in open, sunny sites.

Ecological Interactions and Invasiveness

Catharanthus roseus exhibits self-compatibility in reproduction, with over 30% of flowers capable of autonomous self-pollination through intra-flower contact between stigma and anthers, though pollinators substantially enhance fruit set and seed production per fruit. Flowers are primarily pollinated by butterflies and moths, with additional visitation by bees. The plant's indole alkaloids, including catharanthine present on surfaces, serve as chemical defenses against chewing herbivores, reducing feeding damage and exhibiting insecticidal effects on such as and . These secondary metabolites contribute to its resistance against pests, though documented natural herbivores remain limited. Outside its native range, C. roseus has naturalized widely in tropical and subtropical regions, becoming invasive in areas including parts of , , , the , , Eastern , and southeast , as well as coastal dunes and scrub in . Its invasiveness stems from rapid growth, prolific self-seeding, and seed dispersal via wind, water, , and human activity, favoring disturbed habitats like roadsides, grasslands, and open woodlands. Ecological impacts include formation of monospecific stands that displace native vegetation through competition for resources, with the plant demonstrating efficient water and nutrient use under stress conditions, potentially outcompeting locals in invaded ecosystems. Additionally, its poses risks to grazing animals, causing in .

Cultivation Practices

Propagation and Agronomy

Catharanthus roseus is propagated primarily by and stem cuttings. Seeds are sown in a well-drained medium at temperatures of 24–27°C, with typically occurring within 10–20 days under consistent moisture and light exposure. For indoor starts, seeds should be initiated 12–16 weeks before the last to ensure robust transplants. Stem cuttings, taken from healthy semi-ripe shoots in early fall or spring, root readily in or a moist perlite-sand mix, often achieving higher success rates with the application of rooting hormones and maintenance of high . Agronomically, C. roseus thrives in tropical and subtropical climates with full sun exposure and minimum temperatures above 15°C, though it tolerates partial shade and performs as an in temperate zones. It adapts to various types, including sandy, loamy, and clay, but requires excellent drainage to prevent , with optimal growth in humus-rich, slightly acidic to neutral light soils; it exhibits high once established but low tolerance for waterlogged or highly saline conditions. Planting is best in warm soils during early summer, using transplants spaced at 30 cm between plants and 50 cm between rows to maximize yield and airflow, minimizing risk from overhead . Fertilization with NPK at rates of 150:40:30 kg/ha, applied basally and as top-dressings, supports vigorous growth and accumulation in field cultivation. Pruning is recommended to maintain plant health and promote flowering. In winter, prune to remove spent flowers, diseased branches, dead branches, dense branches, and overly long stems to conserve nutrients and promote successful overwintering, resulting in more branches and increased flowering the following year. For potted plants, a supplementary overwintering method involves covering the plant with a transparent plastic bag supported by stakes, loosely securing the bottom or leaving gaps for airflow, and ventilating daily by removing the bag to prevent condensation and mold; however, risks of fungal growth from high humidity make this auxiliary, with primary recommendation for indoor management above 10°C given the plant's sensitivity below this threshold. For routine maintenance, promptly remove spent flowers and pinch tops to encourage branching and significantly boost flower quantity. Guidelines recommend simple pruning once per season to maintain a full plant shape and sustain continuous blooming. In commercial settings, enhanced air movement and light levels beyond standard conditions improve plant quality and reduce fungal issues.

Optimization for Alkaloid Production

Optimization of production in Catharanthus roseus has focused on overcoming the plant's naturally low yields of key anticancer alkaloids (TIAs), such as and , which constitute less than 0.02% and 0.2% of leaf dry weight, respectively. Biotechnological strategies, including cell and tissue cultures, have been employed to enhance productivity, with hairy root cultures induced by rhizogenes transformation yielding up to several-fold higher levels compared to undifferentiated cells, due to stable genetic integration and sustained growth. These cultures optimize and accumulation through medium adjustments, such as source variations and precursor feeding, achieving and yields exceeding 1 mg/g dry weight in optimized shake-flask conditions. Elicitation techniques represent a primary method for boosting TIA flux, with biotic elicitors like fungal extracts from Fusarium oxysporum increasing vincristine and vinblastine yields by 2- to 4-fold in embryogenic tissues through induced defense responses and pathway upregulation. Chemical elicitors, including methyl jasmonate (MJ) at 100-200 μM, elicit 2- to 5-fold elevations in suspension cultures by activating jasmonate signaling, which transcriptionally induces TIA biosynthetic genes like STR and TDC. Yeast extract (0.5-1 g/L) similarly enhances vinblastine and vincristine in protoplast-derived plantlets by mimicking pathogen attack, with reported increases of up to 3-fold when applied during late exponential growth phases. Abiotic factors, such as optimized LED lighting with high blue wavelengths (70-80% blue), elevate vinblastine and vincristine by 1.5- to 2-fold via photoreceptor-mediated gene expression, outperforming red or white light spectra in indoor hydroponic systems. Genetic and approaches target rate-limiting steps in TIA pathways, with overexpression of transcription factors like CrMYC1 or CrWRKY1 redirecting flux toward low-abundance TIAs, yielding up to 10-fold increases in vindoline and catharanthine precursors in hairy roots. Synthetic polyploidization via colchicine treatment (0.1-0.5%) produces tetraploid lines with 20-50% higher content due to effects and enlarged cells facilitating accumulation. Agronomic optimizations, including foliar ascorbic acid sprays at 750 mg/L, raise by 20% and by 16% in field-grown plants by mitigating and enhancing enzyme activities like . Hybrid breeding leverages parental profiles, with F1 generations showing additive for total alkaloids up to 1.5-fold over parents. Despite advances, scalability challenges persist, as yields rarely exceed 1-2 mg/L for dimeric TIAs, necessitating integrated strategies combining elicitation with for commercial viability.

Biochemical Composition

Primary Metabolites and Alkaloids

Catharanthus roseus contains primary metabolites essential for basic physiological processes, including carbohydrates such as glucose, , and , which serve as energy sources and structural components. Amino acids like , γ-aminobutyric acid (GABA), aspartate, and glutamate are also prominent, supporting protein synthesis and nitrogen metabolism, with their levels influenced by environmental factors such as light intensity—reduced light decreases concentrations of several . Organic acids and contribute to cellular integrity and signaling, though specific lipid profiles remain less characterized compared to sugars and . In contrast to primary metabolites, the plant's is dominated by indole alkaloids (TIAs), with over 130 distinct types identified across its tissues. These alkaloids, biosynthesized via pathways involving strictosidine as a key intermediate, accumulate primarily in leaves and stems for anticancer compounds like vindoline and catharanthine (monomeric precursors), while contain higher levels of and . Dimeric TIAs such as (typically 0.01–0.3 mg/g dry weight in leaves under standard conditions) and (lower, around 0.0002–0.05 mg/g) are present in trace amounts, necessitating large-scale extraction for pharmaceutical use. Alkaloid content varies by genotype, developmental stage, and abiotic stresses; for instance, vindoline levels can reach 0.891 mg/g in controls, escalating under elicitor treatments, while vinblastine may hit 0.307 mg/g. These compounds exhibit pharmacological potency despite low yields, with TIAs comprising up to 1–3% of leaf dry weight in optimized cultivars.

Biosynthetic Pathways

The terpenoid indole alkaloids (TIAs) in Catharanthus roseus are synthesized through a complex pathway integrating shikimate-derived precursors and terpenoids, with strictosidine serving as the foundational intermediate formed by strictosidine synthase (STR) from (derived from via tryptophan decarboxylase, TDC) and secologanin (from the mevalonate-independent pathway via and loganin intermediates). This early phase occurs in multiple cell types, including internal parenchyma and idioblasts, before downstream compartmentalization. The pathway branches post-strictosidine, yielding over 100 TIAs, with anticancer agents and arising from vindoline and catharanthine coupling. From strictosidine, enzymatic deglycosylation and cyclization via strictosidine glucosidase (SGD) produce preakuammicine, which rearranges to stemmadenine, then cathenamine and ; serves as a hub for branches including the tabersonine route to vindoline and the 19-hydroxytabersonine path to catharanthine. The vindoline branch, active in leaf epidermal cells under light induction, involves seven sequential modifications from tabersonine: hydroxylation by tabersonine 16-hydroxylase (T16H), followed by acetylations, reductions, and methylations via enzymes like tabersonine-16-O-methyltransferase (T16OMT), precondylocarpine acetyltransferase (PAT), and a minovincinine 19-O-acetyltransferase (MAT), culminating in vindoline as identified in 2015 pathway completion studies. Catharanthine biosynthesis diverges earlier, incorporating 19-hydroxylation and subsequent dehydration steps from 19-hydroxytabersonine. Dimerization of vindoline and catharanthine to form anhydrovinblastine (AVLB) is catalyzed by a class III (PRX1) in leaf vacuoles, with subsequent reduction yielding ; arises from N-demethylation by an unidentified P450. Full elucidation of the 31-step pathway, including vindolinine (a Fe(II)/α-ketoglutarate dioxygenase diverting tabersonine flux), was achieved by 2022, highlighting plant-specific enzymes absent in systems. involves transcription factors like ORCA2/3 (AP2/ERF family) activating downstream genes, with environmental cues such as enhancing vindoline accumulation via GATA and PIF factors. Flux bottlenecks persist in mid- and late stages, limiting yields to levels per gram leaf dry weight.

Historical and Traditional Uses

Indigenous Applications

In Madagascar, the endemic origin of Catharanthus roseus, indigenous Malagasy healers traditionally utilized leaves as emetics owing to their bitter and astringent qualities, while roots functioned as purgatives, vermifuges, depuratives, and hemostatics, with applications specifically for toothache relief. Local fishermen and mariners chewed the leaves to alleviate mouth sores, reflecting oral administration in maritime folk practices. Among African indigenous groups, the Bapedi traditional healers of Limpopo Province, , employ root extracts exclusively for treating gonorrhoea, with the plant reported as the most frequently used species by 28 healers across three districts in surveys conducted in 2013. In , leaf infusions serve to manage stomach ulcers; in , ground leaves mixed with milk address mature abscesses; and in , root decoctions relieve dysmenorrhoea. These applications, documented in ethnobotanical records, predate scientific validation of the plant's alkaloids and highlight region-specific preparations like decoctions and infusions, though efficacy remains unverified beyond anecdotal reports in traditional contexts.

Early Scientific Investigations

Catharanthus roseus was first scientifically described by Carl Linnaeus in 1753 as Vinca rosea in Species Plantarum, based on specimens from Madagascar and its ornamental cultivation in Europe. The species was reclassified into the genus Catharanthus in 1837 by Scottish botanist George Don, reflecting its distinct morphology from the European periwinkles (Vinca spp.), including its opposite leaves and salverform corolla. Early botanical studies focused primarily on its taxonomy and horticultural value as an evergreen subshrub with variable flower colors, but chemical analyses were limited until the mid-20th century, with no significant phytochemical isolation reported prior to 1950. Medicinal investigations commenced in the early when Canadian biochemist Robert L. Noble, working in J.B. Collip's at the , tested leaf extracts for antidiabetic potential, prompted by folkloric claims from Jamaican healers of efficacy against . Aqueous extracts from dried leaves, administered to rats at doses of 10-50 mg/kg, failed to lower blood glucose but induced severe , reducing counts by over 90% within days, indicating rather than the expected hypoglycemic effect. This serendipitous observation shifted research toward anticancer applications, with Noble's team confirming antitumor activity in leukemia models by 1954. By 1958, Noble and collaborator T. Beer isolated the vinblastine (initially vincaleukoblastine) from leaf extracts, identifying it as a dimeric responsible for the cytotoxic effects. , a , was subsequently purified around by researchers at , who scaled up production after licensing the compounds from Noble's findings. These isolations marked the transition from empirical testing to targeted , though yields remained low (0.001-0.02% dry weight), necessitating extensive material—up to 500 kg of leaves per gram of . Early clinical trials in the late 1950s demonstrated efficacy against Hodgkin's lymphoma and , establishing the alkaloids' role in despite initial toxicity concerns.

Medicinal Applications

Anticancer Alkaloids and Mechanisms

Catharanthus roseus yields dimeric alkaloids, primarily and , which are extracted from the plant's leaves and exhibit potent anticancer activity. These compounds, along with semi-synthetic derivatives like vindesine, vinorelbine, and vinflunine, belong to the class and have been integral to since their isolation in the late 1950s and early 1960s. concentrations in the plant reach up to 0.2% dry weight in optimized cultivars, while is present in trace amounts, necessitating large-scale extraction processes involving solvent fractionation and . The primary mechanism of action for these alkaloids involves high-affinity binding to β- subunits on , preventing into stable . This disruption inhibits the formation of the mitotic spindle during , causing and subsequent in rapidly proliferating cancer cells. Unlike microtubule-stabilizing agents such as taxanes, vinca alkaloids depolymerize at higher concentrations, leading to dissolution of the cytoskeletal network and interference with intracellular , which amplifies in tumor cells overexpressing . Clinically, targets hematologic malignancies including , Hodgkin's lymphoma, and by halting aberrant cell proliferation in lymphoid tissues. is employed against solid tumors such as testicular , where it contributes to cure rates exceeding 90% in combination regimens, and advanced , often alongside other agents to overcome resistance via synergistic disruption. Both alkaloids demonstrate selectivity for mitotic cells due to their reversible binding kinetics, with dissociation constants around 10^{-6} M, allowing normal cells to recover function post-exposure. Resistance mechanisms, such as mutations or efflux pump overexpression (e.g., ), can diminish efficacy, prompting research into nanoparticle formulations for enhanced delivery.

Clinical Efficacy and Limitations

Vincristine and , dimeric alkaloids derived from Catharanthus roseus, exhibit established clinical efficacy primarily in hematologic malignancies and certain solid tumors through , which arrests cells in and induces . is integral to multi-agent regimens for (ALL), , and , contributing to complete remission rates exceeding 80% in pediatric ALL protocols like those incorporating , , and . similarly enhances outcomes in (e.g., regimen) and testicular germ cell tumors, with response rates around 70-90% in advanced cases when combined with and . These agents' efficacy stems from their ability to synergize with other chemotherapeutics, reducing tumor burden and improving event-free survival, as evidenced by long-term data from cooperative trials since the 1960s. Despite their utility, limitations include dose-limiting for , manifesting as in up to 60% of patients, which often necessitates dose reductions or discontinuation after cumulative doses exceeding 10-15 mg/m². , while less neurotoxic, induces myelosuppression, elevating infection risk via (grade 3-4 in 50-70% of cycles) and causing alopecia, gastrointestinal disturbances, and pulmonary toxicity in prolonged use. Both alkaloids face challenges from tumor resistance mechanisms, such as β-tubulin mutations altering binding affinity, which diminish response in relapsed or settings. Supply constraints arise from low alkaloid yields in C. roseus (vincristine <0.0002% dry weight), prompting reliance on semisynthetic production and limiting scalability for broader applications beyond approved indications. Emerging clinical trials explore liposomal formulations or conjugates to mitigate and enhance tumor targeting, but gains remain modest, with neuropathy persistence noted even in modified delivery systems. Overall, while these alkaloids remain indispensable in pediatric , their restricts monotherapy use and underscores the need for adjunctive neuroprotective strategies.

Contemporary Research

Biotechnological Enhancements

Hairy root cultures of Catharanthus roseus, established via Agrobacterium rhizogenes transformation, enable sustained production of terpenoid indole alkaloids (TIAs) at levels exceeding those from wild-type plants, with optimized bioreactor conditions yielding up to 1.5-fold higher vinblastine accumulation compared to undifferentiated cell suspensions. Metabolic engineering in these cultures has further amplified TIA biosynthesis; for instance, co-overexpression of the transcription factor ORCA3 and strictosidine glucosidase resulted in a 2-3-fold increase in serpentine and ajmalicine content. Similarly, combinatorial modules involving ORCA3, BIS1, and MYC2 transcription factors boosted vindoline and catharanthine precursors, precursors to anticancer dimeric TIAs, by redirecting flux through the monoterpenoid indole alkaloid pathway. Genetic transformation protocols have advanced to support targeted enhancements, with Agrobacterium tumefaciens strains GV3101 achieving transformation efficiencies of up to 11% in leaf explants, facilitating stable integration of biosynthetic genes for TIA pathway manipulation. Recent innovations include simplified nanocarrier-based delivery using green-synthesized superparamagnetic iron oxide nanoparticles, which improved transient in protoplasts without disruption, enabling rapid prototyping of metabolic edits. These methods address recalcitrance to regeneration, with LBA4404 strains promoting superior shoot induction post-transformation. In vitro polyploidization via treatment has produced tetraploid C. roseus lines exhibiting 1.5-2-fold elevations in total content, including , attributed to enlarged cells and upregulated biosynthetic enzyme expression. approaches, such as pathway refactoring in hairy roots, have engineered compartmentalized expression of strictosidine synthase and downstream enzymes, yielding heterologously produced TIAs at microgram-per-gram dry weight scales. Seed bacterization with siderophore-producing represents an emerging non-transgenic enhancement, increasing monoterpenoid yields by 20-30% through improved nutrient mobilization and elicitor effects. These biotechnological interventions collectively mitigate the plant's naturally low TIA yields (0.0002% for in leaves), supporting scalable pharmaceutical production.

Emerging Pharmacological Insights

Recent investigations have highlighted the antidiabetic potential of Catharanthus roseus extracts. In a 2025 study using streptozotocin-induced diabetic mice, of ethanolic extract at 200 mg/kg body weight over 20 days significantly lowered blood glucose levels, achieving effects comparable to the standard drug glibenclamide at 10 mg/kg. assays demonstrated inhibitory activity against α-amylase (IC₅₀ = 0.62 ± 0.02 mg/ml) and α-glucosidase (IC₅₀ = 0.64 ± 0.01 mg/ml), suggesting interference with carbohydrate digestion enzymes. The extract also normalized lipid profiles in diabetic models by reducing total , triglycerides, cholesterol (LDL-c), and cholesterol (VLDL-c). Antiarthritic effects were observed in the same study through inhibition of protein denaturation, with the ethanolic extract achieving 81.57% inhibition at 1600 µg/ml, approaching aspirin's efficacy of 89.63%. Molecular docking analysis identified binding affinities of key compounds, such as ergost-5-en-3-ol, to targets like COX-2 (up to -9.9 kcal/mol), supporting mechanisms relevant to . In , emerging data from 2025 cultivar-specific analyses under conditions show enhanced of the anticancer (VCR). The 'C-Red' produced VCR concentrations allowing 1 g extraction from 38.8 kg fresh leaves, a 13.7-fold improvement over conventional yields requiring 530 kg. Flowers of 'C-XDR-PN' and 'C-XDR-WT' s exhibited 3.15- to 4.05-fold higher VCR than leaves, indicating organ-specific optimization potential. These s modulate signaling pathways and activity, contributing to in lymphomas and leukemias. Broader pharmacological profiles include antimicrobial and anti-inflammatory actions, with alkaloids like vindesine and vinorelbine extending applications to hypertension and infections, though clinical translation remains limited by extraction challenges. Such findings underscore C. roseus versatility, prompting further mechanistic studies on non-oncologic targets.

Toxicity Profile

Toxic Alkaloids and Symptoms

Catharanthus roseus produces over 70 indole alkaloids, with vinca alkaloids such as vincristine, vinblastine, vindoline, and catharanthine being the primary toxic compounds responsible for its poisonous effects; these alkaloids disrupt microtubule assembly by binding to tubulin, impairing cell division and leading to cytotoxicity across multiple organ systems. In therapeutic contexts, purified vincristine and vinblastine exhibit dose-dependent toxicity, but raw plant ingestion delivers uncontrolled doses alongside other alkaloids, exacerbating risks due to variable concentrations in leaves, stems, flowers, and seeds. Human poisoning from ingestion typically manifests with acute gastrointestinal symptoms including nausea, vomiting, severe abdominal pain, and diarrhea, often progressing within hours to cardiovascular effects such as hypotension, bradycardia, and arrhythmias; neurological involvement may include peripheral neuropathy, myalgias, seizures, tremors, and in severe cases, coma or paralysis. A 2024 case report documented misuse of C. roseus herb causing fever, cholestatic jaundice from hepatotoxicity, and gastric ulcers mimicking acute cholangitis, with elevated liver enzymes and bilirubin resolving only after cessation and supportive care. Hematologic suppression, including leukopenia and thrombocytopenia, can occur subacutely, mirroring chemotherapeutic side effects but without medical oversight. In animals, symptoms mirror toxicity but vary by and exposure level; dogs and cats exhibit , , depression, , incoordination, tremors, seizures, and potential fatality from central nervous system depression. Horses experience gastrointestinal upset including and proportional to ingested plant mass. In sheep, accidental has led to salivation, dyspnea, anorexia, bloody , , and pathological findings of gastrointestinal hemorrhage and renal tubular , with mortality rates up to 100% in affected herds without intervention. All plant parts are toxic, with onset of signs within 1-3 hours post-ingestion, underscoring the need for prompt and supportive therapy in veterinary cases.

Risk Mitigation in Use

In pharmaceutical applications, vinca alkaloids extracted from Catharanthus roseus, such as and , require intravenous administration exclusively to mitigate risks of severe , myelosuppression, and cardiovascular effects associated with non-IV routes. Preparation in small-volume intravenous infusion bags, rather than syringes, prevents accidental intrathecal injection, which has resulted in irreversible neurological damage or death in documented cases. Regulatory guidelines from agencies like the FDA and TGA mandate pharmacy-based dilution and labeling with warnings such as "FOR INTRAVENOUS USE ONLY" on all packaging and preparations to enforce these protocols. Dosing precision, typically calculated by (e.g., at 1.4–2 mg/m² weekly), combined with regular monitoring of blood counts, nerve function, and hepatic/renal parameters, allows early detection and management of adverse effects like or . Contraindications include demyelinating disorders, and drug interactions with inhibitors necessitate dose reductions to avoid accumulation. For traditional, , or self-administered uses of crude extracts, is contraindicated due to variable content leading to unpredictable , including , , and ; professional medical oversight is essential if pursued. In ornamental contexts, placement beyond reach of children and pets minimizes accidental risks, as all parts contain vinca capable of inducing , , and cardiac arrhythmias. Supportive treatments like activated for recent exposures and symptomatic care (e.g., antiemetics, fluids) form the basis of , underscoring prevention through restricted access.

Bioprospecting and Economic Impacts

Commercial Development History

In the early 1950s, researchers at the , including Robert L. Noble and Charles T. Beer, initiated screening of Catharanthus roseus (then classified as Vinca rosea) extracts for potential antidiabetic activity, prompted by folk medicinal claims from and the suggesting efficacy against . Instead of hypoglycemic effects, the extracts induced profound in test rats, redirecting focus toward antineoplastic properties. This serendipitous observation, first reported in 1952, laid the groundwork for identifying bioactive alkaloids, though initial yields from plant material were low, necessitating collaboration with pharmaceutical entities for purification and scaling. Eli Lilly and Company partnered with the Canadian team in the mid-1950s, leading to the isolation of vinblastine (initially vincaleukoblastine) in 1958 by Gordon Svoboda's group through systematic fractionation of leaf extracts. Vinblastine demonstrated efficacy against murine leukemias and was commercialized by Lilly as Velban in 1961, marking the first oncology drug derived from the plant's alkaloids. Shortly thereafter, vincristine (leurocristine) was isolated in 1961, approved by the U.S. Food and Drug Administration in July 1963 under the brand Oncovin, and rapidly adopted for treating childhood leukemia and Hodgkin's lymphoma due to its distinct mechanism of microtubule inhibition. These dimeric indole alkaloids, present in trace amounts (less than 0.0002% dry weight), drove early commercial extraction from cultivated plants in India and Madagascar, though supply constraints prompted Lilly to invest in semi-synthetic production methods by the 1970s. By the late 1960s, annual global sales of and exceeded $100 million, establishing C. roseus as a cornerstone of plant-derived therapeutics and spurring regulations, though without formal benefit-sharing with until later international agreements. The drugs' success validated screening but highlighted challenges in sustainable sourcing, as wild harvesting depleted native populations, leading to expanded cultivation and ongoing yield optimization efforts.

Controversies in Benefit Sharing

The development of and from Catharanthus roseus, native to and traditionally used by local communities for treating , exemplifies early practices lacking equitable benefit sharing. In the early , a Canadian , followed by , screened the plant for hypoglycemic effects based on ethnobotanical leads but serendipitously identified its anticancer alkaloids, which inhibit by binding . Commercialized by starting in the late , these drugs generated over $100 million in annual sales by the 1980s, with estimated profits exceeding $88 million, yet received no royalties, technology transfers, or other compensations. This case has been widely critiqued as biopiracy, where biological resources and associated from developing nations are appropriated by multinational firms without reciprocal benefits, exacerbating global inequities in pharmaceutical innovation. Critics argue that the indirect reliance on Malagasy ethnomedical cues—despite the novel anticancer application—warranted recognition and , a view echoed in academic analyses highlighting how such extractions deprive source communities of economic opportunities. Eli Lilly maintained that no formal agreements existed and that the therapeutic shift from to represented independent scientific advancement, dismissing retrospective claims amid the absence of prior benefit-sharing demands from Malagasy authorities. The controversy predates the 1992 , which formalized access and benefit-sharing principles, and the 2010 , rendering legal enforcement retroactively infeasible; nonetheless, it underscores persistent challenges in implementing fair mechanisms, as post hoc benefit shares in similar deals often constitute minimal profit fractions (e.g., 1-3%). Subsequent U.S. collections (1960-1982) of thousands of global plant samples, including from , further amplified debates over uncompensated resource use, informing calls for prior and mutually agreed terms in contemporary .

References

  1. https://plants.usda.gov/plant-profile/CARO14
  2. https://www.kew.org/plants/madagascar-periwinkle
  3. https://www.missouribotanicalgarden.org/PlantFinder/PlantFinderDetails.aspx?kempercode=a569
  4. https://plants.ces.ncsu.edu/plants/catharanthus-roseus/
  5. https://edis.ifas.ufl.edu/publication/FP112
  6. https://cen.acs.org/biological-chemistry/natural-products/Periwinkle-gives-cancer-busting-secrets/96/i19
  7. https://www.sciencedirect.com/science/article/pii/S0254629925003825
  8. https://www.kew.org/read-and-watch/catharanthus-roseus-cancer-killing-plant
  9. https://plants.usda.gov/classification/43293
  10. https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:77880-1
  11. https://ucjeps.berkeley.edu/eflora/eflora_display.php?tid=18352
  12. http://www.theplantlist.org/tpl1.1/record/kew-35719
  13. https://www.nparks.gov.sg/florafaunaweb/flora/1/7/1792
  14. https://www.sciencedirect.com/topics/immunology-and-microbiology/catharanthus-roseus
  15. https://bsapubs.onlinelibrary.wiley.com/doi/full/10.1002/ajb2.1067
  16. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0068518
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC10721464/
  18. https://www.researchgate.net/publication/223961300_Cytogenetic_characterization_and_genome_size_of_the_medicinal_plant_Catharanthus_roseus_L_G_Don
  19. https://www.publish.csiro.au/cp/pdf/CP24363
  20. https://www.nature.com/articles/s41589-023-01327-0
  21. https://www.sciencedirect.com/science/article/abs/pii/S0168945220300108
  22. https://portal.wiktrop.org/species/show/357
  23. https://www.worldfloraonline.org/taxon/wfo-0000819442
  24. https://www.plantsrescue.com/posts/catharanthus-roseus
  25. https://www.idpublications.org/wp-content/uploads/2016/05/Full-Paper-COMPARATIVE-MORPH-ANATOMICAL-LEAF-CHARACTERS-OF-NERIUM-OLEANDER-AND-CATHARANTHUS.pdf
  26. https://www.zobodat.at/pdf/PHY_17_1_2_0151-0158.pdf
  27. https://jpp.journals.ekb.eg/article_36260_73cbc7dea288d57f12719e659825f342.pdf
  28. https://www.researchgate.net/figure/Leaf-stem-and-root-anatomy-of-Catharanthus-roseus_fig1_369411877
  29. https://www.cabidigitallibrary.org/doi/full/10.1079/cabicompendium.16884
  30. https://www.researchgate.net/publication/289069616_Pollination_and_seed_set_in_vinca_Catharanthus_roseus_L_G_Don
  31. https://www.sciencedirect.com/science/article/pii/S0254629923000042
  32. https://www.cambridge.org/core/journals/plant-genetic-resources/article/breeding-medicinal-plant-periwinkle-catharanthus-roseus-l-g-don-a-review/730E3E281BA0891353BD8B4E4D217AC0
  33. https://www.scribd.com/presentation/751122431/Periwinkle-Breeding
  34. https://pubmed.ncbi.nlm.nih.gov/15598715/
  35. https://pubmed.ncbi.nlm.nih.gov/23077233/
  36. https://keys.lucidcentral.org/keys/v3/eafrinet/weeds/key/weeds/Media/Html/Catharanthus_roseus_%28Madagascar_Periwinkle%29.htm
  37. https://tropical.theferns.info/viewtropical.php?id=Catharanthus+roseus
  38. https://www.cal-ipc.org/plants/profile/catharanthus-roseus-profile/
  39. https://greg.app/madagascar-periwinkle-cooler-apricot-overview/
  40. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/catharanthus
  41. https://pubmed.ncbi.nlm.nih.gov/39718032/
  42. https://scite.ai/reports/characterization-of-a-new-potyvirus-vb0j8V
  43. http://www.hear.org/pier/wra/pacific/catharanthus_roseus_htmlwra.htm
  44. https://www.sciencedirect.com/science/article/abs/pii/S0098847220303312
  45. https://www.cal-ipc.org/plants/risk/catharanthus-roseus-risk/
  46. https://harvesttotable.com/how-to-grow-vinca-rosea-catharanthus/
  47. https://agriculture.vikaspedia.in/viewcontent/agriculture/crop-production/package-of-practices/medicinal-and-aromatic-plants/catharanthus-roseus-1?lgn=en
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4312627/
  49. https://d.sodatekata.net/page/1961
  50. https://jingyan.baidu.com/article/b87fe19ea29ec3131935687b.html
  51. https://fieldreport.caes.uga.edu/publications/B1219/a-guide-for-commercial-production-of-vinca/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC4441158/
  53. https://pubmed.ncbi.nlm.nih.gov/18600658/
  54. http://onlinelibrary.wiley.com/doi/10.1002/bit.260370709/pdf
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC10574240/
  56. https://www.researchgate.net/publication/228776757_Increasing_alkaloid_production_from_Catharanthus_roseus_suspensions_through_methyl_jasmonate_elicitation
  57. https://www.sciencedirect.com/science/article/pii/S0102695X1730042X
  58. https://www.sciencedirect.com/science/article/pii/S2214750025001167
  59. https://microbiologyjournal.org/biosynthesis-and-modulation-of-terpenoid-indole-alkaloids-in-catharanthus-roseus-a-review-of-targeting-genes-and-secondary-metabolites/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3327198/
  61. https://www.nature.com/articles/s41598-025-91103-y
  62. http://pse.agriculturejournals.cz/artkey/pse-202201-0002_changing-in-the-production-of-anticancer-drugs-vinblastine-and-vincristine-in-catharanthus-roseus-l-g-don.php
  63. https://rjb.scione.com/cms/fulltext.php?id=65
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC11586840/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC6152753/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC6272713/
  67. https://www.intechopen.com/chapters/64496
  68. https://sabraojournal.org/wp-content/uploads/2023/08/SABRAO-J-Breed-Genet-55-4-1342-1350-MS23-82.pdf
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC10735432/
  70. https://pubmed.ncbi.nlm.nih.gov/25159992/
  71. https://www.pnas.org/doi/10.1073/pnas.1501821112
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC10593122/
  73. https://www.nature.com/articles/s41467-022-31100-1
  74. https://academic.oup.com/plphys/article/180/3/1336/6117555
  75. https://www.chelseaphysicgarden.co.uk/the-many-lives-of-a-medicinal-superstar-delving-into-the-global-story-of-catharanthus-roseus/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC3824514/
  77. https://onlinelibrary.wiley.com/doi/10.1002/pbc.31247
  78. https://cdnsciencepub.com/doi/10.1139/o90-197
  79. https://pubmed.ncbi.nlm.nih.gov/2085431/
  80. https://utppublishing.com/doi/10.3138/cbmh.17.1.155
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC3883245/
  82. https://pubmed.ncbi.nlm.nih.gov/39120434/
  83. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/vinblastine
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC10209376/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC9305860/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC9102595/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC9161525/
  88. https://www.ncbi.nlm.nih.gov/books/NBK537122/
  89. https://www.ncbi.nlm.nih.gov/books/NBK12718/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC8468923/
  91. https://www.auctoresonline.org/article/chemotherapy-medication-of-vincristine-and-vinblastine
  92. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/572238
  93. https://www.mayoclinic.org/drugs-supplements/vinblastine-intravenous-route/description/drg-20066688
  94. https://medlineplus.gov/druginfo/meds/a682848.html
  95. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01614/full
  96. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1703637/full
  97. https://www.ncbi.nlm.nih.gov/books/NBK557842/
  98. https://pubmed.ncbi.nlm.nih.gov/34564757/
  99. https://www.sciencedirect.com/science/article/pii/S2214030122000037
  100. https://www.sciencedirect.com/science/article/abs/pii/S1096717618300508
  101. https://www.sciencedirect.com/science/article/pii/S2405844024166200
  102. https://pubmed.ncbi.nlm.nih.gov/40759855/
  103. https://pubmed.ncbi.nlm.nih.gov/35333954/
  104. https://pubmed.ncbi.nlm.nih.gov/39831919/
  105. https://link.springer.com/article/10.1007/s10529-021-03179-x
  106. https://www.nature.com/articles/s41598-025-96643-x
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC12389407/
  108. https://www.sciencedirect.com/science/article/pii/S2667142524000873
  109. https://www.sciencedirect.com/science/article/pii/S0040603117300503
  110. https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-024-04441-1
  111. https://www.aspca.org/pet-care/aspca-poison-control/toxic-and-non-toxic-plants/periwinkle
  112. https://plantaddicts.com/are-vinca-poisonous/
  113. https://www.researchgate.net/publication/283722093_Clinical_and_Pathological_Investigations_of_Accidental_Catharanthus_roseus_Toxicity_in_Sheep
  114. https://www.merckvetmanual.com/toxicology/poisonous-plants/houseplants-and-ornamentals-toxic-to-animals
  115. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-vinca-alkaloid-labeling-preparation-intravenous-infusion-bags-only
  116. https://www.tga.gov.au/news/safety-updates/administer-vinca-alkaloids-intravenous-infusion-only
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC10993546/
  118. https://www.acepnow.com/article/toxicology-answer-the-periwinkle/
  119. https://pubmed.ncbi.nlm.nih.gov/14526803/
  120. https://www.jic.ac.uk/blog/vinblastine-and-vincristine-life-saving-drugs-from-a-periwinkle/
  121. https://pubmed.ncbi.nlm.nih.gov/16143373/
  122. https://www.lilly.com/about/history
  123. https://www.princeton.edu/~ota/disk3/1983/8315/831513.PDF
  124. https://synapse.ucsf.edu/articles/2019/05/21/date-ucsf-history-green-gold
  125. https://case.edu/affil/sce/authorship-spring2004/rosy.html
  126. https://www.iegindia.org/upload/publication/Workpap/wp221.pdf
  127. https://digitalcommons.law.ou.edu/cgi/viewcontent.cgi?article=1121&context=ailr
  128. https://psfaculty.plantsciences.ucdavis.edu/gepts/Gepts.%25202004.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.